about
Sequencing the unsequenceable: expanded CGG-repeat alleles of the fragile X geneThe clinical relevance of neuroplasticity in corticostriatal networks during operant learningLearning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach us.Treatment of neurodevelopmental disorders in adulthoodThe pathophysiology of fragile X (and what it teaches us about synapses)NINDS epilepsy and autism spectrum disorders workshop reportFragile X syndrome: A review of clinical managementFMRP targets distinct mRNA sequence elements to regulate protein expressionAMPAKINE enhancement of social interaction in the BTBR mouse model of autismUsing mouse models of autism spectrum disorders to study the neurotoxicology of gene-environment interactionsTranslational regulation of NeuroD1 expression by FMRP: involvement in glutamatergic neuronal differentiation of cultured rat primary neural progenitor cellsRole of Genetics in the Etiology of Autistic Spectrum Disorder: Towards a Hierarchical Diagnostic Strategy.Progress toward therapeutic potential for AFQ056 in Fragile X syndrome.Fragile X syndrome: mechanistic insights and therapeutic avenues regarding the role of potassium channels.Translational animal models of autism and neurodevelopmental disorders.Psychiatric symptoms in boys with fragile X syndrome: a comparison with nonsyndromic autism spectrum disorder.Climbing the branches of a family tree: diagnosis of fragile X syndrome.A 'cure' for Down syndrome: what do parents want?FMR1 CGG allele size and prevalence ascertained through newborn screening in the United StatesGene × Environment interactions in autism spectrum disorders: role of epigenetic mechanisms.The fragile X syndrome-autism comorbidity: what do we really know?Mass spectrometry as a tool for studying autism spectrum disorder.Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis.Fragile X syndrome: clinical, cytogenetic and molecular screening among autism spectrum disorder children in Indonesia.Molecular Advances Leading to Treatment Implications for Fragile X Premutation CarriersDeletion of glutamate delta-1 receptor in mouse leads to enhanced working memory and deficit in fear conditioning.PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndromeFRAGILE X SYNDROME: PSYCHIATRIC MANIFESTATIONS, ASSESSMENT AND EMERGING THERAPIESEXPLAIN Fragile-X: an explorative, longitudinal study on the characterization, treatment pathways, and patient-related outcomes of Fragile X Syndrome.Autism Symptomatology in Boys with Fragile X Syndrome: A Cross Sectional Developmental Trajectories Comparison with Nonsyndromic Autism Spectrum DisorderCharacterization, treatment patterns, and patient-related outcomes of patients with Fragile X syndrome in Germany: final results of the observational EXPLAIN-FXS study.Impaired activity-dependent FMRP translation and enhanced mGluR-dependent LTD in Fragile X premutation miceUsing Drosophila as a tool to identify Pharmacological Therapies for Fragile X SyndromePotential therapeutic approaches for Angelman syndrome.A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndromeGlycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice.The role of ionotropic glutamate receptors in childhood neurodevelopmental disorders: autism spectrum disorders and fragile x syndrome.Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome.Making headway with genetic diagnostics of intellectual disabilities.The potential of biomarkers in psychiatry: focus on proteomics.
P2860
Q24596776-837B9C9C-85A9-459C-9FC0-1B0D4F3AED13Q26849466-7040FEFC-AA30-448B-8EE6-658B63BA4370Q26866506-D21E2327-3D35-49EC-B405-C96C08D1A3AEQ27000307-43889207-EEB5-489B-9924-54EBB999C251Q27010675-5AA293B5-1B9C-4C98-8A79-2D5242E33595Q27022529-3363D68C-0412-419C-BA02-8FDC01E7B9C3Q28076950-3CB7FE0C-9731-49AB-92C4-BB3AF82DAE2CQ28117931-3883577F-95E2-47B2-AD51-48D6F7F504F5Q28388762-8F0E2671-4EE0-4304-ACF3-0FC489B17040Q28392778-85EE9DB7-6729-4A00-9E61-517E8128626BQ28771393-D6E5102F-C6A8-4D67-963B-D2A457CA4601Q30235312-37E01C02-99A9-44E6-BE2A-7E6EAC5733C3Q30383696-DB650108-839A-46A3-918A-065322CCBCC7Q30448604-8E639810-EE18-4C6D-A61F-54C613298DD0Q30459992-231AEC7A-5F6C-4185-AA99-63DD775DC764Q33565886-5BA2CB83-1056-438D-B6AF-CCA773E2A0A1Q33671154-DEC17619-CCD7-449F-A432-0D9CA6195D90Q33747513-86BB99B0-742C-4B0F-A60A-A5407FDCCF5AQ33781086-B0EA8F10-14FD-45B0-A1FB-F518ACCF2B61Q33997473-5BB9D509-62DE-4C13-9905-08C56827460CQ34349515-5713F7FA-7F7B-405D-B5F6-33B3BA28AD21Q34470350-24C39568-3ECF-431A-9021-221ACAF9A595Q34487591-3BFC0D0F-995F-4E22-A496-779A25666361Q34548559-26B51B22-5772-4928-B3C8-3D192C1F0602Q34575595-060CF225-D3D9-4519-87CB-7666BB538408Q34656462-A3144922-4573-4351-A7DF-8535749C64EDQ34869830-1E8A3D8F-EC63-46A9-BFDD-31760B3EC8FBQ35013074-963A2A77-0157-445C-92A7-6F67DBA12EB5Q35071987-6CAFB750-0972-4F26-918B-79DAD04D4627Q36011656-A51C72B9-052C-4D9B-B785-34EC08F06D62Q36128713-46028B5E-4039-4E9F-BB01-CDF191618FA6Q36626883-85DB72C2-3557-431E-9F16-54A1E63B9016Q36888247-7224CC61-6763-4CDE-BDBC-2E80337B46ABQ36992786-083C5BCF-A25A-424A-A0ED-831AD3ECD9E3Q36996583-445CAE24-94E5-4ECD-840D-C6904AE47864Q37417156-4F7A1872-12E8-456A-A9D4-2FB6D8B3652EQ37559828-71FB4F33-A4C2-4543-8AA9-79636C37C9B1Q37580522-916DB0A7-7653-415C-B479-B4D8FCBB2FA5Q38124929-F753DA6E-5B34-4183-B79A-1A5900B8403EQ38172847-0570D7EF-C748-48D6-ABA0-88B3AA59F13B
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Fragile X syndrome and targeted treatment trials
@nl
Fragile X syndrome and targeted treatment trials.
@ast
Fragile X syndrome and targeted treatment trials.
@en
type
label
Fragile X syndrome and targeted treatment trials
@nl
Fragile X syndrome and targeted treatment trials.
@ast
Fragile X syndrome and targeted treatment trials.
@en
prefLabel
Fragile X syndrome and targeted treatment trials
@nl
Fragile X syndrome and targeted treatment trials.
@ast
Fragile X syndrome and targeted treatment trials.
@en
P2093
P2860
P3181
P1476
Fragile X syndrome and targeted treatment trials.
@en
P2093
Elizabeth Berry-Kravis
Julie Lauterborn
Randi Hagerman
P2860
P304
P3181
P356
10.1007/978-3-642-21649-7_17
P407
P577
2012-01-01T00:00:00Z